Sentynl Therapeutics, Inc. Sustainability Profile
Sentynl Therapeutics, Inc., headquartered in the United States, is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for patients with rare diseases. Founded in 2017, Sentynl has quickly established itself in the industry, focusing on the development and commercialisation of unique treatment options that address unmet medical needs. With a strong emphasis on precision medicine, Sentynl's core products include specialised therapies that leverage cutting-edge research and technology. The company is committed to improving patient outcomes through its robust pipeline and strategic partnerships. Notably, Sentynl has achieved significant milestones in regulatory approvals, positioning itself as a leader in the biopharmaceutical sector. As it continues to expand its operational reach, Sentynl Therapeutics remains at the forefront of transforming healthcare for those affected by rare conditions.
DitchCarbon Score
How does Sentynl Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sentynl Therapeutics, Inc.'s score of 49 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sentynl Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zydus Lifesciences Limited, which may influence its climate commitments and performance metrics. As part of its corporate family, Sentynl Therapeutics inherits climate-related initiatives and performance data from Zydus Lifesciences Limited. However, no specific reduction targets or climate pledges have been documented for Sentynl Therapeutics. The lack of reported emissions and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In the broader context, companies in the biopharmaceutical sector are increasingly recognising the importance of sustainability and are often guided by frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). While Sentynl Therapeutics has not yet established its own targets, it may benefit from the sustainability practices and commitments of its parent company, Zydus Lifesciences Limited, as it seeks to align with industry standards and expectations regarding carbon emissions and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Sentynl Therapeutics, Inc.'s Industry?
How Carbon Intensive is Sentynl Therapeutics, Inc.'s Location?
Sentynl Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sentynl Therapeutics, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
